PRTA
NASDAQProthena Corporation plc
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$9.43+0.04 (+0.37%)
2026-05-212026-08-25
News · 26 weeks55+11%
2026-03-012026-08-23
Mix2690d
- Insider20(77%)
- SEC Filings3(12%)
- Other2(8%)
- Earnings1(4%)
Latest news
25 items- INSIDERLarge owner Scully William P bought $439,430 worth of Ordinary Shares (50,000 units at $8.79), increasing direct ownership by 7% to 800,000 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 3 filed by new insider Fennell Todd W.3 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERLarge owner Scully William P received a gift of 336,000 units of Ordinary Shares and gifted 627,553 units of Ordinary Shares, decreasing direct ownership by 28% to 750,000 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERLarge owner Scully William P received a gift of 251,553 units of Ordinary Shares, increasing direct ownership by 32% to 1,041,553 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERSEC Form 3 filed by new insider Fennell Todd W.3 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERLarge owner Scully William P bought $323,220 worth of Ordinary Shares (37,500 units at $8.62), increasing direct ownership by 4% to 790,000 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- SECSEC Form 10-Q filed by Prothena Corporation plc10-Q - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- SECProthena Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - PROTHENA CORP PUBLIC LTD CO (0001559053) (Filer)
- PRProthena Reports Second Quarter 2026 Financial Results and Business HighlightsNet cash used in operating and investing activities was $25.7 million in the second quarter and net cash provided by operating and investing activities was $3.2 million for the first six months of 2026; quarter-end cash and restricted cash position was $289.1 million Guidance updated to include shares repurchased through July 30, 2026 and now expects to end the year with approximately $259 million (midpoint) in cash, cash equivalents and restricted cash Results from partner Roche evaluating prasinezumab in patients with early Parkinson’s disease from the Phase 2b PADOVA clinical trial published in The Lancet Multiple research collaborations with industry partners ongoing to explor
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Prothena Corporation plcSCHEDULE 13G/A - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
- INSIDERChief Scientific Officer Zago Wagner M. converted options into 51,000 units of Ordinary Shares and returned $436,560 worth of Ordinary Shares to the company (51,000 units at $8.56) (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERChief Accounting Officer Walker Karin L converted options into 15,000 units of Ordinary Shares and returned $128,400 worth of Ordinary Shares to the company (15,000 units at $8.56) (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERChief Development Officer Swanson Chad J. converted options into 51,000 units of Ordinary Shares, returned $349,248 worth of Ordinary Shares to the company (40,800 units at $8.56) and covered exercise/tax liability with 3,467 units of Ordinary Shares, increasing direct ownership by 20% to 40,733 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERChief Operating Officer Smith Brandon S. converted options into 78,000 units of Ordinary Shares and returned $667,680 worth of Ordinary Shares to the company (78,000 units at $8.56) (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERChief Strategy Officer and CFO Nguyen Tran converted options into 57,000 units of Ordinary Shares and returned $487,920 worth of Ordinary Shares to the company (57,000 units at $8.56) (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERPresident and CEO Kinney Gene G. converted options into 84,000 units of Ordinary Shares and returned $719,040 worth of Ordinary Shares to the company (84,000 units at $8.56) (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERChief Strategy Officer Kingston Anne Evans covered exercise/tax liability with 3,498 units of Ordinary Shares and sold $64,919 worth of Ordinary Shares (7,662 units at $8.47) as part of a pre-agreed trading plan, decreasing direct ownership by 17% to 55,782 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERGeneral Counsel & Company Sec. Isaacs Michael John covered exercise/tax liability with 4,694 units of Ordinary Shares and sold $71,055 worth of Ordinary Shares (8,386 units at $8.47) as part of a pre-agreed trading plan, decreasing direct ownership by 27% to 35,745 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- PRProthena to Report Second Quarter 2026 Financial Results on August 6Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its second quarter and first six months of 2026 financial results on Thursday, August 6, 2026, after the close of the U.S. financial markets. Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on August 6. About Prothena Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neuro
- INSIDERLarge owner Scully William P bought $157,990 worth of Ordinary Shares (20,000 units at $7.90), increasing direct ownership by 3% to 756,000 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERLarge owner Scully William P gifted 325,000 units of Ordinary Shares, decreasing direct ownership by 31% to 736,000 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERLarge owner Scully William P bought $1,021,225 worth of Ordinary Shares (125,000 units at $8.17), increasing direct ownership by 13% to 1,061,000 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- INSIDERNew insider Isaacs Michael John claimed ownership of 48,825 units of Ordinary Shares (SEC Form 3)3 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
- SECSEC Form 144 filed by Prothena Corporation plc144 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Subject)
- INSIDERLarge owner Scully William P bought $465,295 worth of Ordinary Shares (50,000 units at $9.31), increasing direct ownership by 6% to 936,000 units (SEC Form 4)4 - PROTHENA CORP PUBLIC LTD CO (0001559053) (Issuer)
PRTA FAQ
6 questionsWhat does Prothena Corporation plc do?
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase 2 clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase 1 clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, frontotemporal dementia, progressive supranuclear palsy, chronic traumatic encephalopathy, and other...Where does PRTA stock trade?
Prothena Corporation plc (PRTA) is listed on NASDAQ.What sector and industry is PRTA in?
Prothena Corporation plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about PRTA?
Prothena Corporation plc has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Underperform with a $400.00 price target on 2025-05-28.What companies are similar to PRTA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare PRTA side-by-side with any of them on Quantisnow.How can I track PRTA on Quantisnow?
Quantisnow aggregates Prothena Corporation plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRTA to receive live email and push alerts on every new disclosure.